Skip to Content

Join the 'Psoriasis' group to help and get support from people like you.

Psoriasis News

Related terms: Erythrodermic Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Palmo-plantar Psoriasis, Psoriasis vulgaris, Pustular Psoriasis

Severe Stress May Send Immune System Into Overdrive

Posted 4 days ago by Drugs.com

TUESDAY, June 19, 2018 – Trauma or intense stress may up your odds of developing an autoimmune disease, a new study suggests. Comparing more than 106,000 people who had stress disorders with more than 1 million people without them, researchers found that stress was tied to a 36 percent greater risk of developing 41 autoimmune diseases, including rheumatoid arthritis, psoriasis, Crohn's disease ...

UCB Announces the Approval of Cimzia (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis

Posted 12 days ago by Drugs.com

Brussels, Belgium – 28th May, 07:00 CEST – UCB announced today that the U.S. Food and Drug Administration (FDA) has approved extending the label for Cimzia (certolizumab pegol) to include a new indication in adults with moderate-to-severe plaque psoriasis. Cimzia is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or pho ...

Lilly's Taltz (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area

Posted 29 May 2018 by Drugs.com

INDIANAPOLIS, May 22, 2018 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area.1 Taltz is the first and only treatment approved by the FDA for moderate-to-severe plaque psoriasis that includes such data in its ...

FDA Approves Ilumya (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis

Posted 22 Mar 2018 by Drugs.com

MUMBAI, India and PRINCETON, N.J., March 21, 2018 /PRNewswire/ – Sun Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Ilumya (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya selectively binds to the p19 subunit of IL-23 and inhibits ...

Pfizer Announces FDA Approval of Xeljanz (tofacitinib) and Xeljanz XR for the Treatment of Active Psoriatic Arthritis

Posted 10 Jan 2018 by Drugs.com

December 14, 2017 - Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has approved Xeljanz 5 mg twice daily (BID) and Xeljanz XR (tofacitinib) extended release 11 mg once daily (QD) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying ...

Whites More Likely Than Others to Seek Help for Psoriasis

Posted 29 Dec 2017 by Drugs.com

THURSDAY, Dec. 28, 2017 – Among people with the skin disease psoriasis, could skin color play a role in whether or not they visit a dermatologist? An analysis of federal government health survey data from 2001 to 2013 found that black, Asian and other minorities are less likely than white people in the United States to see a doctor for treatment of the chronic inflammatory disease. The ...

FDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade

Posted 14 Dec 2017 by Drugs.com

December 13, 2017 – Pfizer Inc. (NYSE:PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Ixifi (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade® (infliximab)* for all eligible indications of the reference product.1 The FDA has approved Ixifi as a ...

Severe Psoriasis May Make Diabetes Increasingly Likely

Posted 20 Nov 2017 by Drugs.com

MONDAY, Nov. 20, 2017 – People with the skin disease psoriasis are at increased risk for type 2 diabetes, and the more severe the psoriasis, the greater their risk, a new study finds. Researchers examined data on nearly 85,000 adults in the United Kingdom, including 8,100 who had psoriasis. Compared with people who did not have psoriasis, the risk for diabetes was 21 percent higher among those ...

Cyndi Lauper's Psoriasis Battle Shows Her 'True Colors'

Posted 25 Oct 2017 by Drugs.com

WEDNESDAY, Oct. 25, 2017 – With her pink tresses and eye-catching stage costumes, pop culture icon Cyndi Lauper was never one to hide. But that's exactly what she wanted to do when she developed psoriasis, which spread to most of her body and sapped her strength before the skin disorder was controlled. Appearing first on her scalp and later covering everything except her face, psoriasis struck ...

Janssen Announces FDA Approval of Stelara (ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis

Posted 18 Oct 2017 by Drugs.com

Horsham, Pa., October 13, 2017 ― Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Stelara (ustekinumab) for the treatment of adolescents (12 years of age or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Today’s approval marks a significant milestone for this age ...

Many Moisturizers Aren't What They Claim to Be

Posted 6 Sep 2017 by Drugs.com

WEDNESDAY, Sept. 6, 2017 – Many skin moisturizers that claim to be fragrance-free or hypoallergenic are not, and may aggravate skin disorders such as psoriasis and eczema, a new study says. Northwestern University researchers examined the top 100 best-selling, whole-body moisturizers sold at Amazon, Target and Walmart for affordability and content. They found that 83 percent of so-called ...

Severe Psoriasis Linked to Higher Risk of Earlier Death

Posted 5 Sep 2017 by Drugs.com

TUESDAY, Sept. 5, 2017 – People with severe cases of the skin disease psoriasis appeared to have almost double the risk of dying during a four-year study than people without the condition, research suggests. But the increased death rate was only seen in those with psoriasis affecting more than 10 percent of their body surface area. For those with less-severe disease, the risk of dying early was ...

FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira

Posted 30 Aug 2017 by Drugs.com

Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including: moderate to severe active rheumatoid arthritis moderate to severe polyarticular juvenile idiopathic arthritis** a ...

Janssen Announces FDA Approval of Tremfya (guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis

Posted 17 Jul 2017 by Drugs.com

Horsham, PA, July 13, 2017 ― Janssen Biotech, Inc. (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine t ...

Promising Results for Ixekizumab Against Psoriatic Arthritis

Posted 26 May 2017 by Drugs.com

FRIDAY, May 26, 2017 – A new drug might help ease the pain and disability of a form of arthritis often linked to psoriasis. According to Stanford University researchers, psoriatic arthritis is an inflammatory joint disorder tied to an out-of-control immune response. The disease affects about one in every 200 people and is often accompanied by the autoimmune skin disorder psoriasis. Psoriatic ...

Page 1 2 3 4 5 6 7 8 Next

Ask a Question

Further Information

Related Condition Support Groups

Plaque Psoriasis, Psoriatic Arthropathy, Dermatological Disorders

Related Drug Support Groups

prednisone, methotrexate, Humira, methylprednisolone, Remicade, triamcinolone, dexamethasone, clobetasol, Therapeutic, view more... Psoriasin, fluocinonide, Stelara, cyclosporine, desonide, Clobex, Kenalog, hydroxyurea, desoximetasone, Elocon, Tazorac, Kenalog-40, Kenalog-10, Dovonex, infliximab, adalimumab, Topicort, Soriatane, Neoral, Lidex, Acthar, Taclonex, acitretin, coal tar, halobetasol, Acthar Gel, HP, Vanos, Cloderm, Olux, Analpram-HC, Cordran, Locoid, Halog, hydrocortisone / pramoxine, feverfew, calcipotriene, Deltasone, Cortizone-10, Dermovate, etanercept, Cordran Tape, Acth, Temovate, Cortaid, Synalar, Locoid Lipocream, Olux-E, Eczema Cream, Aristocort A, Halog-E, Hytone, Inflectra, Ionil T, Enstilar, Anti-Dandruff, anthralin, Vectical, resorcinol, Pandel, Sterapred, Aristospan, Trianex, Aclovate, Encort, Cortaid Maximum Strength, Amjevita, Hycort, Renflexis, Drithocreme, Cyltezo, Methotrexate LPF Sodium, Proctofoam HC, Coal Tar Strong, Zone-A, Verdeso, Oxsoralen-Ultra, Desonate, Liquid Pred, Sterapred DS, Neutrogena T / Gel, Ixifi, clocortolone, Psoriatec, Gengraf, DesOwen, methoxsalen, corticotropin, Dritho-Scalp, ustekinumab, halcinonide, tazarotene, alclometasone, Ultravate, Pramosone, Nutracort, flurandrenolide, Scalp-Aid, Cort-Dome, Genasone / Aloe, Instacort 10, Scalp-Cort, Beta HC, Ivocort, NuZon, Cortizone-5, Dermarest Plus Anti-Itch, U-Cort, Cortizone for Kids, Neutrogena T-Scalp, Dermarest Dricort, Rederm, etretinate, Dermtex HC, Cortaid Intensive Therapy, Cortizone-10 Plus, Sarnol-HC, 8-MOP, Recort Plus, Acticort 100, Aeroseb-HC, trioxsalen, Texacort, Hydrocort cream, Ala-Cort, Penecort, Cotacort, Lacticare-HC, Ala-Scalp HP, Cortane, Cortaid with Aloe, Aloe Cort, Nogenic HC, Aquanil HC, Caldecort, Corticaine, Corticreme, Delcort, Dermol HC, Dermolate, Gly-Cort, Itch-X Lotion, Hi-Cor, prednicarbate, Soriatane CK, Ultravate PAC, Z-Xtra, Dermotic, Pediaderm HC, Carb-O-Lac HP, Carb-O-Lac5, Carmol HC, Keratol HC, Zithranol, Synalar Ointment, Synalar TS, Otrexup, Dermasorb HC, Rasuvo, Clodan, coal tar / salicylic acid, Halac, MG217 Psoriasis, Tarsum, betamethasone / calcipotriene, NuCort, ammonium lactate / urea, Psoriatar, amcinonide, alefacept, Nolix, Impoyz, Pediaderm TA, Anthrascalp, Olux / Olux-E Kit, Scalacort, Temovate E, efalizumab, Dermacort, Taclonex Scalp, PC Tar, Dermagesic, Resinol, Scytera, MD Hydrocortisone, Fluocinonide-E, diflorasone, Hydrocortisone 1% In Absorbase, Anthraforte, Analpram E, Cormax Scalp, Derma-Smoothe / FS (Scalp), Zithranol-RR, Ala-Scalp, Halonate, Pramosone E, Sorilux, coal tar / salicylic acid / sulfur, Calcitrene, HC Pram, Westcort, Ultralytic, Cetacort, Synemol, Embeline E, Clobevate, Medotar, Delonide, Fototar, Florone, Psorcon, Florone E, Psorcon E, ApexiCon E, Fluonid, Flurosyn, Temovate Emollient, FS Shampoo, Synalar-HP, Licon, Dermacin, Fluex, MG217 Medicated Tar, Triacet, Triderm, Aricin, Aristocort R, Delta-Tritex, Cormax, Tegison, Rx Triamcinolone, Apexicon, Scalpicin, Instacort, Epifoam, Cordran SP, Lidex-E, Capex, X-Seb T Plus, Derma-Smoothe / FS, Dermatop, Raptiva, Maxiflor, Folex PFS, A-Fil, Topicort LP, Meticorten, LoKara, Orasone, Prednicen-M, Tridesilon, Prednicot, Clinacort, Anthra-Derm, Doak Tar, Micanol, Flutex, Cinalog, Cort-Dome High Potency, Orion Coal Tar, Reme-T, Exorex, Polytar Mild, Psoriderm, Clinitar, Alphosyl, Alphosyl 2 in 1, Carbo-Dome, Amevive, Doak Oil Forte, Apha Keri Tar, Linotar, Cutar, Apha Keri Tar Gel, Linotar Gel 2, Linotar Gel 3, Pinetarsol Tar, R A Acne, Dovobet, Utralytic, Ultralytic 2, Trexall, ammonium lactate / halobetasol, benzocaine / pyrilamine / zinc oxide, Elta Tar, Doctar, Cinolar, Tegrin Medicated, Embeline, Enzone, Zone-A Forte, Rectocort HC, Novacort, Hydropram, HC Pramoxine, G-TAR, Zeprime Tar Emulsion, DHS Tar Shampoo, Ionil T Plus, Pentrax, Polytar, Estar, Balnetar, Betatar Gel, Theraplex T, Cyclocort, Oxipor VHC, Doak Tar Oil, Neutrogena T / Derm, Pentrax Gold, Tegrin Medicated Soap, Psorigel, Zetar